Novel Interleukin Inhibitors and the Paradoxical Development of Vitiligo: A Systematic Review

J Cutan Med Surg. 2023 Mar-Apr;27(2):167-168. doi: 10.1177/12034754231157646. Epub 2023 Feb 20.

Authors

Karanvir S Raman¹, Gohar Zakaryan², Anna-Lisa Tam-Vi Nguyen³, Jorge R Georgakopoulos⁴, Jensen Yeung⁴

Affiliations

¹ 12358 Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
² 62703 Faculty of Health Science, McMaster University, Hamilton, Ontario, Canada.
³ 70384 Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
⁴ 793812366 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

PMID: 36802834
DOI: 10.1177/12034754231157646

No abstract available

Keywords: interleukin; ixekizumab; secukinumab; tildrakizumab; ustekinumab; vitiligo.

Publication types

Systematic Review
Letter

MeSH terms

Antibodies, Monoclonal
Humans
Interleukin Inhibitors
Interleukin-23
Psoriasis*
Treatment Outcome
Ustekinumab
Vitiligo* / chemically induced
Vitiligo* / drug therapy

Substances

Interleukin Inhibitors
Antibodies, Monoclonal
Ustekinumab
Interleukin-23